Vickers Vantage I in a regulatory filing said it has called a Nov. 9 meeting for shareholders to vote on the proposed combination with Scilex, a majority-owned subsidiary of Sorrento Therapeutics.
The SPAC’s sponsors have agreed to cancel 40% of their private warrants if redemptions exceed 75%. Just under 30% of the SPAC’s shares outstanding were redeemed ahead of a July deadline extension vote on the deal.
As announced in March, Scilex was originally expected to have a pro forma equity value post-money of $1.64 billion. Read more.
